General information
  • Disease category Endocrinological diseases (non cancer) , Nutritional and Metabolic diseases (BASEC)
  • Recruitment status recruitment ongoing (BASEC/ICTRP)
  • Trial sites
    Lausanne
    (BASEC)
  • Contact Lucie Favre Lucie.Favre@chuv.ch (BASEC)
  • Data Source(s) BASEC: Import from 15.01.2026 ICTRP: N/A
  • Last update 15.01.2026 17:10
HumRes63458 | SNCTP000005737 | BASEC2022-01389

Intravenous iron-induced hypophosphatemia in patients who have undergone Roux-en-Y gastric bypass: a single-blind randomized clinical trial comparing iron isomaltoside (Monofer®) and ferric carboxymaltose (Ferinject®)

  • Disease category Endocrinological diseases (non cancer) , Nutritional and Metabolic diseases (BASEC)
  • Recruitment status recruitment ongoing (BASEC/ICTRP)
  • Trial sites
    Lausanne
    (BASEC)
  • Contact Lucie Favre Lucie.Favre@chuv.ch (BASEC)
  • Data Source(s) BASEC: Import from 15.01.2026 ICTRP: N/A
  • Last update 15.01.2026 17:10

Summary description of the study

Patients who are followed up after bariatric surgery occasionally require iron infusion. A side effect of this infusion is hypophosphatemia (low phosphate levels in the blood). Symptoms of hypophosphatemia include general weakness and fatigue. In very rare cases, this drop in phosphate levels can cause symptoms of muscle weakness or breathing difficulties. We propose to test two formulations of intravenous iron for the potential occurrence of a drop in phosphate levels. A total of 4 visits to our clinic will be necessary (one for the infusion and 3 subsequently on a weekly basis for blood and urine tests). An electrocardiogram and a grip strength test (strength of your hand flexion) will also be performed.

(BASEC)

Intervention under investigation

Patients who require iron infusion will receive iron isomaltoside (Monofer®) or ferric carboxymaltose (Ferinject®). The patient will not know which type of iron they received. A total of 4 visits to our clinic will be necessary (one for the infusion and 3 weekly for blood and urine tests).

(BASEC)

Disease under investigation

Hypophosphatemia after iron infusion in patients who have undergone bariatric surgery (Roux-en-Y gastric bypass)

(BASEC)

Criteria for participation in trial
1. >12 months post bariatric surgery (RYGB) 2. ferritin <50 ug/l 3. Failure or intolerance to oral iron supplementation (BASEC)

Exclusion criteria
1. Patients with known hypersensitivity to the iron preparation and/or anaphylaxis, regardless of the cause. 2. Pregnant or breastfeeding women 3. Patients who have received an intravenous iron infusion in the last 3 months. (BASEC)

Trial sites

Lausanne

(BASEC)

not available

Sponsor

CHUV

(BASEC)

Contact

Contact Person Switzerland

Lucie Favre

+41-21 314 05 48

Lucie.Favre@chuv.ch

CHUV

(BASEC)

Scientific Information

not available

Name of the authorising ethics committee (for multicentre studies, only the lead committee)

Ethics Committee Vaud

(BASEC)

Date of authorisation

21.12.2023

(BASEC)


ICTRP Trial ID
not available

Official title (approved by ethics committee)
Intravenous iron-induced hypophosphatemia in patients with Roux-en-Y gastric bypass: a single-blind, randomized clinical trial comparing iron isomaltoside (Monofer®) and ferric carboxymaltose (Ferinject®) (BASEC)

Academic title
not available

Public title
not available

Disease under investigation
not available

Intervention under investigation
not available

Type of trial
not available

Trial design
not available

Inclusion/Exclusion criteria
not available

not available

Primary and secondary end points
not available

not available

Registration date
not available

Incorporation of the first participant
not available

Secondary sponsors
not available

Additional contacts
not available

Secondary trial IDs
not available

Results-Individual Participant Data (IPD)
not available

Further information on the trial
not available

Results of the trial

Results summary

not available

Link to the results in the primary register

not available